Better Health for All

Avadel's primary product, LUMRYZ, is FDA-approved for narcolepsy in adults and pediatric patients (7 years and older), demonstrating statistically significant improvements in excessive daytime sleepiness and cataplexy.

It also addresses challenges of twice-nightly oxybate therapy, where 75.3% of patients reported missing doses and 31.8% experienced injuries. However, LUMRYZ is a Schedule III controlled substance (active ingredient GHB is Schedule I) with a boxed warning for serious risks including respiratory depression, hypotension, changes in alertness, fainting, and death. It can cause mental health problems (confusion, hallucinations, depression, suicidality) and physical dependence. In one study, 15.9% of patients discontinued LUMRYZ due to adverse reactions. The company's R&D expenses for Q3 2025 were $27.0 million, up from $3.8 million in Q3 2024, including a $20 million upfront payment for a new GABAB receptor agonist. LUMRYZ is covered for over 90% of commercially insured patients, with co-pay assistance potentially reducing costs to $0, and patient assistance programs for uninsured/underinsured individuals. However, Medicaid formulary access is pending for 10% of patients. The company has a REMS program and provides detailed safety information, but the product's active ingredient is a Schedule I controlled substance, and it can cause physical dependence. LUMRYZ has been granted seven years of Orphan Drug Exclusivity for both adult and pediatric indications, with a second seven-year period granted in October 2024.

Fair Pay & Worker Respect

The company offers competitive health, dental, vision, and life insurance for all employees, allowing them to choose plans that work best for them and their families.

The ratio of the Chief Executive Officer's compensation to the median annual total compensation of all other employees is 27:1. None of the company's employees are subject to a union or other collective bargaining agreement.

No War, No Weapons

Avadel Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing pharmaceutical products for unmet medical needs, primarily in sleep disorders.

The provided articles describe the company's core business as pharmaceuticals, with its main product being LUMRYZ for narcolepsy. There is no evidence in the articles to suggest any involvement in arms manufacturing, military contracts, dual-use technologies, sales to sanctioned regimes, or any other activities related to war or weapons. Therefore, all KPIs under the 'No War, No Weapons' value are not applicable to Avadel's core operations as described.

Respect for Cultures & Communities

The provided articles consistently focus on Avadel's corporate compliance program, ethical conduct, and career opportunities. They explicitly state that no specific data or metrics related to community engagement, cultural sensitivity, or respect for cultures and communities are available.

Therefore, there is no evidence to score any of the KPIs for the 'Respect for Cultures & Communities' value.

Safe & Smart Tech

Avadel Pharmaceuticals plc reported no material cybersecurity threats or incidents for 2024.

The company states it implements security measures, including encryption, to prevent unauthorized access to data. It performs periodic security testing and risk assessments. Avadel's European Privacy Policy indicates data is retained only as necessary for collection purposes, with direct identifiers eliminated for service improvement. The company explicitly states compliance with Data Protection Laws, including GDPR, and other relevant EU regulations, as well as applicable U.S. state laws. Users have rights to access, rectify, object to, erase, restrict processing, and data portability of their personal data, and can unsubscribe from direct marketing. Passwords are used for access to services, but no further details on authentication strength or multi-factor authentication availability are provided.